First-Line Treatment in ER-Positive, HER2-Negative Metastatic Breast Cancer

In this segment, Dr. Gregory Vidal outlines what a typical first-line treatment plan looks like for patients with ER-positive, HER2-negative metastatic breast cancer. He explains that treatment generally begins with endocrine therapy, which targets the cancer’s dependence on estrogen signaling. In many cases, this therapy is combined with a CDK4/6 inhibitor to enhance effectiveness and improve disease control. Dr. Vidal emphasizes that the goal of first-line therapy in metastatic disease is to slow cancer progression, maintain quality of life, and extend survival while minimizing toxicity. He also notes that treatment selection is individualized based on prior therapies, disease burden, patient health status, and biomarker findings. This segment helps patients understand why endocrine-based combinations are often the standard initial approach in ER-positive, HER2-negative metastatic breast cancer and reinforces the importance of a personalized treatment strategy tailored to each patient’s specific clinical situation.